PG 27

Drug Profile

PG 27

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmagenesis
  • Class Antirheumatics
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Rheumatoid arthritis
  • Discontinued Autoimmune disorders; Graft-versus-host disease

Most Recent Events

  • 20 Oct 2017 PG 27 is available for licensing in (excluding Taiwan, China) as of 20 Oct 2017. http://www.pharmagenesis.net/Pipeline.htm
  • 19 Oct 2015 Preclinical development is ongoing in USA
  • 23 Jul 1998 No-Development-Reported for Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top